Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma.

Fifty-six patients with disseminated malignant melanoma were randomly allocated to two treatment groups. The first group C received combination chemotherapy consisting of DTIC and ICRF 159. The second group (C+I) received the same chemotherapy but were also immunized with 2 X 10(7) irradiated alloge...

Descripción completa

Detalles Bibliográficos
Autores principales: Newlands, E. S., Oon, C. J., Roberts, J. T., Elliott, P., Mould, R. F., Topham, C., Madden, F. J., Newton, K. A., Westbury, G.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1976
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2025153/
https://www.ncbi.nlm.nih.gov/pubmed/962994
Descripción
Sumario:Fifty-six patients with disseminated malignant melanoma were randomly allocated to two treatment groups. The first group C received combination chemotherapy consisting of DTIC and ICRF 159. The second group (C+I) received the same chemotherapy but were also immunized with 2 X 10(7) irradiated allogeneic melanoma cells mixed with 50 mug of percutaneous BCG. The survival rates in both treatment groups C and (C+I) were not significantly different, and only minor enhancement of the chemotherapy was found in the (C+I) group. A similar pattern of tissue response was observed in both groups: lymph node, skin and, to some extent liver metastases, respond better than other sites.

Ejemplares similares